Skip to content

Ischemic heart disease — epidemiology and global burden

TL;DR — In 2021, ischemic heart disease (IHD) accounted for an estimated 254.3 million prevalent cases, 9.0 million deaths, and 188.4 million disability-adjusted life-years (DALYs); the age-standardized death rate fell 31.6% from 1990 while absolute burden remained high because population growth and aging offset rate reductions (Yang 2025, PMID 40841929). GBD 2023 still ranks IHD as the largest cardiovascular contributor to DALYs, within 19.2 million total cardiovascular deaths (GBD CVD 2023 Collaborators 2025, PMID 40990886). High systolic blood pressure and high LDL cholesterol are the leading modifiable contributors, but risk exposure, access to diagnosis, acute reperfusion, secondary prevention, and rehabilitation are distributed unequally (Yang 2025, PMID 40841929; Aminorroaya 2022, PMID 34041535). Age-standardization and absolute counts answer different questions and should never be interchanged. The actionable epidemiologic problem is no longer whether effective prevention exists, but why delivery remains weakest where premature mortality is highest.

Case definition and measurement

IHD burden estimates combine fatal and non-fatal manifestations of coronary atherosclerosis: myocardial infarction, chronic ischemic disease, and related sequelae. Contemporary clinical taxonomies divide presentation into acute coronary syndromes and chronic coronary disease/syndromes, but GBD estimates use modeled cause definitions designed for cross-country comparability rather than bedside classification (Bhatt 2022, PMID 35166796; Virani 2023, PMID 37471501; Vrints 2024, PMID 39210710).

Measure What it answers Principal limitation
Prevalence How many people are living with IHD? Sensitive to survival, diagnostic access, and coding
Incidence How many new events occur? Misses silent and out-of-hospital events
Death count How many deaths require services and prevention? Rises with population size and aging
Age-standardized death rate Is underlying population risk changing? Does not describe the absolute service burden
DALYs How much fatal and non-fatal health loss occurs? Combines modeled years lived with disability and years of life lost
Quality-of-care index How effectively are treatable outcomes being prevented? Composite model; not a direct audit of individual care

Death certificates, hospital registries, surveillance studies, and covariate models differ in coverage. Consequently, GBD uncertainty intervals are part of the estimate, not decorative precision (Yang 2025, PMID 40841929; GBD CVD 2023 Collaborators 2025, PMID 40990886).

Global burden snapshot

Indicator Estimate Year and population Method/source
People living with IHD 254.3 million (95% UI 221.4–295.5 million) Global, 2021 GBD 2021 modeling (Yang 2025, PMID 40841929)
IHD deaths 9.0 million (95% UI 8.3–9.5 million) Global, 2021 GBD 2021 modeling (Yang 2025, PMID 40841929)
IHD DALYs 188.4 million Global, 2021 GBD 2021 modeling (Yang 2025, PMID 40841929)
Change in age-standardized IHD death rate −31.6% Global, 1990–2021 GBD trend estimate (Yang 2025, PMID 40841929)
All cardiovascular deaths 19.2 million Global, 2023 GBD 2023 modeling (GBD CVD 2023 Collaborators 2025, PMID 40990886)
All cardiovascular prevalent cases 626 million Global, 2023 GBD 2023 modeling (GBD CVD 2023 Collaborators 2025, PMID 40990886)

The coexistence of falling standardized rates and persistent or rising absolute counts is not contradictory. Rate reduction reflects improved prevention and treatment within an age structure; counts additionally reflect more people and more years lived at ages when coronary disease becomes common (GBD CVD 2023 Collaborators 2025, PMID 40990886).

Geography and development gradient

The global mean conceals a steep gradient. Low- and lower-middle-SDI settings carry a disproportionate share of premature cardiovascular mortality and have less consistent access to risk-factor detection, emergency transport, reperfusion, evidence-based discharge therapy, and rehabilitation (GBD CVD 2023 Collaborators 2025, PMID 40990886; Aminorroaya 2022, PMID 34041535).

An IHD quality-of-care index constructed from mortality-to-incidence and prevalence relationships improved globally between 1990 and 2017 but remained strongly associated with national development level. That metric is imperfect, yet its persistent cross-national spread is consistent with a delivery gap rather than a shortage of efficacious interventions (Aminorroaya 2022, PMID 34041535).

System layer High-resource advantage Epidemiologic consequence when absent
Primary prevention Repeated BP/lipid measurement and long-term treatment More first events at younger ages
Emergency response Symptom recognition, ambulance ECG, cath-lab networks Longer ischemic time and more early death
Acute care PCI, antithrombotics, intensive monitoring Higher case fatality and mechanical complications
Secondary prevention Affordable statins, antiplatelets, RAAS therapy, follow-up Recurrent MI, stroke, and heart failure
Rehabilitation Structured exercise, risk-factor and psychosocial care Lower functional recovery and adherence

The SECURE trial shows that simplifying secondary prevention into a polypill can reduce events after myocardial infarction, while cardiac-rehabilitation meta-analysis shows reduced cardiovascular mortality; these are implementation-ready interventions, not hypothetical technologies (Castellano 2022, PMID 36018037; Dibben 2023, PMID 36746187).

Risk-factor attribution

High systolic blood pressure and high LDL cholesterol are the leading attributable risks in the GBD IHD analysis (Yang 2025, PMID 40841929). Elevated LDL-C is now quantified as a distinct global exposure: the 2023 GBD analysis reports substantial and uneven cardiovascular burden and emphasizes the large treatment gap despite inexpensive therapy (GBD LDL Collaborators 2026, PMID 42525403).

Domain Relation to population burden Important qualification
LDL-containing lipoproteins Causal cumulative exposure; pharmacologic reduction lowers recurrent events A single late-life measurement understates lifetime exposure
Systolic blood pressure Major attributable risk across regions Detection and sustained control matter more than one clinic reading
Tobacco Strong preventable trigger of first and recurrent events Exposure includes second-hand smoke and varies by sex and region
Diabetes/adiposity Accelerates atherosclerosis and worsens outcomes Prevalence is rising in many settings with falling smoking rates
Physical inactivity/diet Operate through BP, lipids, glycemia, weight, and independent pathways Measurement is heterogeneous and confounded
Genetic susceptibility Alters lifetime risk and age at onset Polygenic scores do not replace modifiable-risk treatment

Among people at high polygenic risk, adherence to a favorable lifestyle was associated with substantially lower coronary risk, arguing against genetic fatalism (Khera 2016, PMID 27959714). Polygenic scores can modestly refine primary-prevention prediction, but clinical utility depends on calibration, ancestry representation, and whether risk disclosure changes management (Landmesser 2018, PMID 30322267; Marston 2023, PMID 36576811).

Age, sex, and social patterning

IHD incidence rises steeply with age, yet premature disease produces disproportionate years of life lost. Reviews of young-adult prevention emphasize that cumulative exposure can be substantial before conventional 10-year risk crosses a treatment threshold (Stone 2022, PMID 35210038).

Women often develop obstructive coronary disease later than men but are not protected from IHD. Sex and gender influence risk exposure, symptom interpretation, referral, coronary phenotype, and outcomes; women are overrepresented in non-obstructive ischemic syndromes and may experience diagnostic delay when presentation does not match a stereotyped chest-pain narrative (Grant 2024, PMID 38548464; Regitz-Zagrosek 2023, PMID 36316574).

Source of disparity Examples Research implication
Biology Vessel size, hormonal transitions, plaque erosion, microvascular dysfunction Report sex-stratified mechanisms and outcomes
Clinical recognition Different symptom frequencies; attribution to non-cardiac causes Measure delay and missed diagnosis directly
Trial representation Lower enrollment of women, older adults, and advanced CKD Avoid extrapolating average effects without subgroup uncertainty
Social determinants Income, education, rurality, medication affordability Link treatment access to outcomes rather than treating geography as biology
Mental health Depression/anxiety co-occur with vascular events and impair recovery Integrate psychosocial detection with secondary prevention

Advanced chronic kidney disease is an example of simultaneous high risk and evidence scarcity: patients have extensive coronary disease but were excluded from many trials, and routine invasive management does not reproduce the assumptions derived from broader stable-CAD populations (Bangalore 2020, PMID 32227756).

Mental-health burden after coronary events

Depression and anxiety are common after myocardial infarction and are associated with impaired quality of life, adherence, and return to activity. Meta-analyses document bidirectional co-occurrence between depression/anxiety and MI or stroke, and substantial post-MI prevalence of depression, anxiety, and post-traumatic stress symptoms (Aw 2023, PMID 36610338; Chong 2025, PMID 40142595). These outcomes are generally omitted from death-and-MI composites even though they influence lived burden and rehabilitation uptake.

  • A falling age-standardized rate does not mean health-system demand is falling (Yang 2025, PMID 40841929).
  • A rising count does not prove individual risk is worsening; population growth and aging may dominate (GBD CVD 2023 Collaborators 2025, PMID 40990886).
  • Cross-country model rankings should generate hypotheses and accountability, not substitute for local registries (Aminorroaya 2022, PMID 34041535).
  • Prevalent-case counts include survivors with very different symptom, anatomy, and recurrence risk; they are not a count of active angina (Virani 2023, PMID 37471501).
  • Risk attribution describes preventable burden under modeled counterfactuals; it is not the effect expected from a single intervention deployed today (Yang 2025, PMID 40841929).

Minimum dataset for a useful national IHD dashboard

Layer Numerator Denominator/comparator Stratification required
Burden Incident MI, prevalent IHD, deaths, DALYs Population and age structure Age, sex, region, deprivation
Acute access Reperfused STEMI; invasive NSTEMI Eligible ACS presentations Geography, transfer status, sex
Timeliness Symptom-to-contact and contact-to-device time All eligible events Direct arrival versus transfer
Prevention LDL/BP control and smoking cessation Survivors eligible for treatment Cost, insurance, clinic access
Rehabilitation Enrollment and completion Eligible discharges Referral source and delivery mode
Recurrence Recurrent MI/stroke/HF admission Event-free survivors Treatment exposure and adherence
Lived outcome Angina, function, distress Surviving cohort Obstructive versus INOCA phenotype

This structure prevents a country from appearing successful because case-fatality fell while incidence, recurrence, disability, or inequitable access remained high. It also separates model-derived burden from directly audited care processes (Aminorroaya 2022, PMID 34041535; Dibben 2023, PMID 36746187).

Landmark comparative epidemiology

Study frame Quantified contribution Limitation for inference
INTERHEART In 15,152 cases and 14,820 controls across 52 countries, nine modifiable factors accounted for most population-attributable MI risk, with similar directional associations across regions and sexes (Yusuf 2004, PMID 15364185). Case-control attributable fractions depend on exposure measurement, model specification, and the counterfactual distribution.
PURE Prospective follow-up of 155,722 adults in 21 countries linked a small set of modifiable exposures with incident CVD and mortality, while the relative importance of exposures differed by country income (Yusuf 2020, PMID 31492503). Community cohorts do not directly measure access to reperfusion or secondary-prevention quality after IHD onset.
GBD 2021 The broader 371-disease analysis provides internally comparable incidence, prevalence, YLD, DALY, and HALE estimates for 204 countries (GBD 2021 Diseases Collaborators 2024, PMID 38642570). Modeled estimates are not surveillance counts; sparse locations borrow information from covariates and neighboring data.
IHD-specific GBD Estimated 2021 IHD prevalence was 254.3 million, deaths 9.0 million, and DALYs 188.4 million (Yang 2025, PMID 40841929). These outputs inherit cause-of-death miscoding and diagnostic-access differences.
Care quality The GBD-derived quality-of-care index showed large and persistent cross-country inequality from 1990–2017 (Aminorroaya 2022, PMID 34041535). An index combines heterogeneous proxies and cannot identify the failing delivery step.
Young-adult MI US hospitalization data showed rising AMI burden and sex differences among young adults over two decades (Arora 2019, PMID 30586725). Hospitalization trends mix true incidence with coding, troponin, referral, and survival changes.
Sex/gender Biological and gendered pathways jointly shape presentation, exposure, care, and outcomes (Regitz-Zagrosek 2023, PMID 36316574; Grant 2024, PMID 38548464). Binary routine data often cannot separate sex biology, gender, pregnancy history, treatment, and deprivation.
Secondary-prevention delivery A review of Indian ACS, heart-failure and outpatient registries and quality-improvement programmes (CREATE, TN-STEMI, ACS-QUIK, PIQIP) describes how secondary-prevention quality is measured there and where data remain absent (Rehman 2020, PMID 33189191). Facility registries under-represent people who never reach care and should not be generalized to all LMIC systems.

Numerators, denominators, and apparent contradictions

Age-standardized death rates can fall while absolute deaths rise because population growth and aging increase the denominator at risk. Incidence can appear to rise after adoption of high-sensitivity troponin even if severe transmural MI falls; conversely, regions with weak diagnostic access may undercount both nonfatal events and deaths. The recent global cause-of-death and cardiovascular-burden analyses therefore should be read beside—not averaged with—country registries (GBD 2021 Causes of Death Collaborators 2024, PMID 38582094; Global Burden of Cardiovascular Diseases 2025, PMID 40990886).

Attribution is similarly non-additive. LDL-C, blood pressure, smoking, diabetes/adiposity, air pollution, kidney disease, and socioeconomic conditions interact along causal pathways; summing separately modeled population-attributable fractions can exceed 100%. Genetic risk can identify higher baseline susceptibility, but healthy lifestyle was associated with lower event risk across genetic strata, arguing against deterministic interpretation (Khera 2016, PMID 27959714). Elevated LDL burden remains a major modeled contributor, yet the 2023 GBD LDL analysis is an attributable-risk model rather than a randomized treatment estimate (GBD 2023 LDL Collaborators 2026, PMID 42525403).

Personalized-prevention frameworks emphasize cumulative exposure and absolute benefit rather than a single cross-sectional risk label (Landmesser 2018, PMID 30322267). That conceptual shift is epidemiologically important but should not be counted as direct evidence that a particular screening program improves population outcomes.

Mental-health comorbidity changes both burden and recovery: pooled observational data link depression/anxiety with co-prevalent or incident MI/stroke, but heterogeneity and bidirectionality require cautious causal interpretation (Aw 2023, PMID 36610338).

European prevention guidance illustrates how surveillance estimates are converted into total-risk and implementation priorities, while also showing that a recommendation document is not itself an epidemiologic denominator (Visseren 2021, PMID 34458905).

Burden is exposure, access, and age structure—not one prevalence curve

A GBD 2021 secondary analysis estimated 612 million people living with cardiovascular disease in 2021 and 26.8% of global deaths attributable to CVD; from 1990, age-standardized prevalence rose 0.88% to 7,179 per 100,000 while mortality and DALY rates fell 34.3% and 33.0%, respectively (Tan 2025, PMID 39847534). These are model-based all-CVD estimates, not IHD counts, but they quantify why falling rates can coexist with expanding caseloads and why IHD should not be interpreted outside the wider vascular burden.

Access gradients exist within as well as between countries. A 57-study review found lower socioeconomic status associated most consistently with reduced coronary angiography/procedural access; associations with medication and rehabilitation access appeared in only about half the studies and were stronger with individual-level SES and without universal coverage (Schröder 2016, PMID 27288969). This pattern supports measuring each care-funnel step rather than assuming insurance coverage equals effective access.

Environmental and life-course exposures broaden the attribution frame. GBD 2015 estimated ambient PM2.5 caused 4.2 million deaths (95% UI 3.7–4.8 million) and 103.1 million DALYs in 2015 across IHD and four other outcomes, with 59% of deaths in East and South Asia; attribution used modeled exposure and integrated exposure-response functions rather than trial evidence (Cohen 2017, PMID 28408086). Among people aged 15–39 years, global CVD incidence rose from 126.80 to 129.85 per 100,000 and prevalence from 1,477.54 to 1,645.32 between 1990 and 2019 even as mortality fell from 19.83 to 15.12 per 100,000; IHD prevalence specifically increased (Sun 2023, PMID 37365627).

Open questions

  • Which combinations of primary-care lipid/BP programs, prehospital networks, affordable essential medicines, and rehabilitation produce the largest reduction in premature IHD mortality per unit cost in low-SDI settings? The quality-of-care gradient identifies the problem but not the optimal delivery package (Aminorroaya 2022, PMID 34041535).
  • How much of the apparent sex gap in IHD incidence reflects biology versus misclassification of INOCA and under-recognition of myocardial infarction? (Grant 2024, PMID 38548464)
  • Can polypill delivery and hybrid/home rehabilitation close recurrent-event gaps at national scale while preserving individualized contraindication management? (Castellano 2022, PMID 36018037; Dibben 2023, PMID 36746187)
  • How should polygenic risk be calibrated across ancestries before it is used to allocate preventive therapy? (Marston 2023, PMID 36576811)
  • Which surveillance sources can reduce dependence on modeled estimates in regions with the largest uncertainty intervals? (GBD CVD 2023 Collaborators 2025, PMID 40990886)

References

  1. Yang L, et al. Global, regional and national burden of ischemic heart disease and its attributable risk factors from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021. BMC Cardiovasc Disord. 2025;25:625. PMID 40841929
  2. Global Burden of Cardiovascular Diseases and Risks 2023 Collaborators, et al. Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023. J Am Coll Cardiol. 2025;86:2167-2243. PMID 40990886
  3. Aminorroaya A, et al. Global, regional, and national quality of care of ischaemic heart disease from 1990 to 2017: a systematic analysis for the Global Burden of Disease Study 2017. Eur J Prev Cardiol. 2022;29:371-379. PMID 34041535
  4. Bhatt DL, et al. Diagnosis and Treatment of Acute Coronary Syndromes: A Review. JAMA. 2022;327:662-675. PMID 35166796
  5. Virani SS, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148:e9-e119. PMID 37471501
  6. Vrints C, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45:3415-3537. PMID 39210710
  7. Castellano JM, et al. Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022;387:967-977. PMID 36018037
  8. Dibben GO, et al. Exercise-based cardiac rehabilitation for coronary heart disease: a meta-analysis. Eur Heart J. 2023;44:452-469. PMID 36746187
  9. GBD 2023 LDL Cholesterol Collaborators, et al. Global Burden of Elevated LDL-C: Findings From the Global Burden of Disease Study 2023. JAMA. 2026;336:673-698. PMID 42525403
  10. Khera AV, et al. Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. N Engl J Med. 2016;375:2349-2358. PMID 27959714
  11. Landmesser U, et al. Coronary disease prevention: towards a more personalised approach. Eur J Prev Cardiol. 2018;25:1884-1886. PMID 30322267
  12. Marston NA, et al. Predictive Utility of a Coronary Artery Disease Polygenic Risk Score in Primary Prevention. JAMA Cardiol. 2023;8:130-137. PMID 36576811
  13. Stone NJ, et al. Managing Atherosclerotic Cardiovascular Risk in Young Adults: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022;79:819-836. PMID 35210038
  14. Grant E, et al. Ischemic Heart Disease in Women. Med Clin North Am. 2024;108:567-579. PMID 38548464
  15. Regitz-Zagrosek V, et al. Gender medicine: effects of sex and gender on cardiovascular disease manifestation and outcomes. Nat Rev Cardiol. 2023;20:236-247. PMID 36316574
  16. Bangalore S, et al. Management of Coronary Disease in Patients with Advanced Kidney Disease. N Engl J Med. 2020;382:1608-1618. PMID 32227756
  17. Aw PY, et al. Co-prevalence and incidence of myocardial infarction and/or stroke in patients with depression and/or anxiety: A systematic review and meta-analysis. J Psychosom Res. 2023;165:111141. PMID 36610338
  18. Chong RJ, et al. Prevalence of Depression, Anxiety and Post-Traumatic Stress Disorder (PTSD) After Acute Myocardial Infarction: A Systematic Review and Meta-Analysis. J Clin Med. 2025;14:1786. PMID 40142595
  19. Yusuf S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-52. PMID 15364185
  20. Yusuf S, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet. 2020;395:795-808. PMID 31492503
  21. GBD 2021 Diseases and Injuries Collaborators, et al. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403:2133-2161. PMID 38642570
  22. Arora S, et al. Twenty Year Trends and Sex Differences in Young Adults Hospitalized With Acute Myocardial Infarction. Circulation. 2019;139:1047-1056. PMID 30586725
  23. Rehman H, et al. Secondary prevention of cardiovascular diseases in India: Findings from registries and large cohorts. Indian Heart J. 2020;72:337-344. PMID 33189191
  24. GBD 2021 Causes of Death Collaborators, et al. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403:2100-2132. PMID 38582094
  25. Visseren FLJ, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227-3337. PMID 34458905
  26. Tan SCW, et al. Global Burden of Cardiovascular Diseases and its Risk Factors, 1990-2021: A Systematic Analysis for the Global Burden of Disease Study 2021. QJM. 2025;118:411-422. PMID 39847534
  27. Schröder SL, et al. Socioeconomic inequalities in access to treatment for coronary heart disease: A systematic review. Int J Cardiol. 2016;219:70-78. PMID 27288969
  28. Cohen AJ, et al. Estimates and 25-year trends of the global burden of disease attributable to ambient air pollution: an analysis of data from the Global Burden of Diseases Study 2015. Lancet. 2017;389:1907-1918. PMID 28408086
  29. Sun J, et al. Global, regional, and national burden of cardiovascular diseases in youths and young adults aged 15-39 years in 204 countries/territories, 1990-2019: a systematic analysis of Global Burden of Disease Study 2019. BMC Med. 2023;21:222. PMID 37365627